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Background: Recruiting to randomized controlled trials is fraught with challenges; with less than one third
recruiting to their original target. In preparation for a trial evaluating the effectiveness of a blood test to screen for
lung cancer (the ECLS trial), we conducted a qualitative study to explore the potential barriers and facilitators that
would impact recruitment.
Methods: Thirty two people recruited from community settings took part in four focus groups in Glasgow and
Dundee (UK). Thematic analysis was used to code the data and develop themes.
Results: Three sub-themes were developed under the larger theme of recruitment strategies. The first of these
themes, recruitment options, considered that participants largely felt that the invitation to participate letter should
come from GPs, with postal reminders and face-to-face reminders during primary care contacts. The second theme
dealt with understanding randomization and issues related to the control group (where bloods were taken but not
tested). Some participants struggled with the concept or need for randomization, or for the need for a control
group. Some reported that they would not consider taking part if allocated to the control group, but others were
motivated to take part even if allocated to the control group by altruism. The final theme considered perceived
barriers to participation and included practical barriers (such as flexible appointments and reimbursement of travel
expenses) and psychosocial barriers (such as feeling stigmatized because of their smoking status and worries about
being coerced into stopping smoking).
Conclusions: Focus groups provided useful information which resulted in numerous changes to proposed trial
documentation and processes. This was in order to address participants information needs, improve
comprehension of the trial documentation, enhance facilitators and remove barriers to participation. The
modifications made in light of these findings may enhance trial recruitment and future trials may wish to consider
use of pretrial focus groups.
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Of all the Medical Research Council and Health Technology
Assessment Programme randomised controlled trials
(RCTs) conducted between 1994 and 2003 (n = 114), less
than one third recruited their original target within the
time originally specified [1]. Bower, Wilson and Mathers
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unless otherwise stated.trials recruited to their original timescale. Therefore, recruit-
ment to trials is clearly one of the biggest challenges for
trialists, and although often dealing with larger participant
pools, recruitment to primary care trials is no exception
[2,3]. The consequences of poor recruitment are: premature
closure of trials, trials that are underpowered to answer the
main research questions (and the dangers associated with
this [4]), wasting of resources and the end-users of research
(patients and clinicians) not benefiting from the intended
outcomes of the trial.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the barriers to participation in RCTs. They identified
both clinician barriers and patient barriers. The latter
included: additional demands of the trial in terms of
additional procedures and appointments, patient prefer-
ences for particular treatments, worry caused by uncer-
tainty of the choice of treatments or random allocation,
and concerns about amount and format of providing
information and obtaining consent. Another systematic
review on barriers to participating in cancer trials [6] identi-
fied system-related and organizational barriers, trial design
barriers and individual health-care provider barriers. They
did not specifically consider participant-related barriers in
terms of how participants’ understanding of the trial might
attract or dissuade them from participation. However, the
authors do suggest a checklist to consider from a patient
perspective, which includes the following questions: ‘What
key information needs to be given to enable patients to feel
more comfortable with the uncertainties involved in the
trial and the concept of clinical equipoise?’, ‘How might the
timing of the request to participate in the trial be sensitively
addressed?’, ‘How might practical barriers such as cost to
patients, transport and time commitments be addressed?’,
and ‘How might the benefits of the trial be explained
to patients?’. They also recommended that trialists
prospectively identify the issues relevant to a particular
trial using their findings as a starting point. Although
this review was specific to cancer, it mostly focused on
cancer treatment trials or hypothetical scenarios, and
not cancer screening trials. The authors acknowledge
that their findings need to be treated with caution due
to a number of threats to the internal and external val-
idity of the included studies. This review also points to
the need for more research on barriers and moderators to
trial participation for cancer screening trials. Furthermore,
Weller and Campbell [7] call for informed uptake whereby
participants make informed choices and are aware of all
the risks and benefits of participation. These authors and
the systematic review by Baron et al. [8] conclude that
more research is required to evaluate the effectiveness
of strategies that improve uptake to various cancer
screening programs.
A Cochrane Review [9] considered the effectiveness
of various strategies to improve recruitment to RCTs,
and recommended using certain strategies (for example,
telephone reminders). This review, however, did not include
any studies that evaluated the effectiveness of using user
tested trial material (including participant information
leaflets [PILs] and consent forms) compared to standard
researcher/industry produced material on recruitment rates.
Knapp et al. [10] made such a comparison for a trial in
acute myeloid leukemia (AML16). The authors con-
cluded that user vetted trial material and procedures
may have a positive impact on recruitment rates.Information about RCTs can be confusing for participants
[11], especially where consent is obtained following pos-
tal information (such as in PILs) as opposed to informa-
tion provided face-to-face [12]. The ethical underpinning
of RCTs assumes participants understand the concepts
of randomization and equipoise, and can therefore give
informed consent [13]. Screening trials have additional
complexities as they typically seek to recruit people without
disease symptoms, the consequences of participation are
less clear than in treatment trials as the results may warrant
further tests, and participants also need to understand the
meaning of screening results.
In preparation for the first UK trial evaluating the ef-
fectiveness of screening using a blood test for the early
detection of lung cancer (the ECLS trial, trial registration
number: NCT01925625), we conducted a qualitative inves-
tigation designed to facilitate recruitment to the trial. This
involved, but was not limited to, eliciting responses from
members of the public representative of the target patient
group to some of the questions posed by Fayter et al. [6].
The aims of the ECLS trial are to assess the effectiveness
and cost effectiveness of the EarlyCDT-Lung test in increas-
ing early stage lung cancer detection, thereby reducing the
rate of late stage presentation and to assess effectiveness
in reducing adverse outcomes, including potential psycho-
logical and behavioral consequences. The trial is set in
general practices, predominately within the lowest quintile
of deprivation measured using the Scottish Index of
Multiple Deprivation, in NHS Tayside and NHS Greater
Glasgow & Clyde. Adults aged 50 to 75 will be eligible to
participate if they are current or former cigarette smokers
with at least 20 pack-years, or have a history of cigarette
smoking less than 20 pack-years plus a family history
(mother, father, brother, sister) of lung cancer and who are
healthy enough to undergo pulmonary resection or stereo-
tactic radiotherapy. Participants will be invited by postal
invitation from their general practitioner. Other members
of the community living in these areas who hear about the
trial though a range of publicity and meet the eligibility
criteria, but are not registered at participating practices,
will also be eligible to participate. The trial has two arms;
the intervention arm, in which participants receive the
EarlyCDT-Lung test, and the control arm, in which partic-
ipants have blood taken which would be used for future
cancer related research but not tested for lung cancer.
The decision to take a blood sample in the control arm
was based on research which suggests altruism can be a
motivating factor for people to participate in research
[5,14] and that participants may prefer to make some con-
tribution to cancer research above that of completing
questionnaires. Those with a positive EarlyCDT-Lung test
will be followed up by imaging studies including chest
x-rays and CT scans. The primary outcome measure is the
difference at 24 months after randomization between the
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at diagnosis in the intervention arm, and those in the
control arm. As the ECLS trial recruits older smokers
and ex-smokers in economically disadvantaged areas,
characterized by relatively low educational attainment
and poor engagement with health services [15], we recog-
nized that this may offer unique challenges to recruitment.
For this reason participants’ views on the following issues
were elicited: issues likely to influence recruitment into
the trial and willingness to be randomized (including re-
cruitment strategies, understanding of risk information,
clinical equipoise and randomization); recruitment and
study documentation (for example the invitation letter
and PILs); factors which may facilitate and hinder trial
participation; and understanding of aspects of the trial
based on the PILs we developed.
Qualitative research is particularly helpful in getting
an in depth appreciation of such views. In fact, it is perhaps
their value in RCTs that has led researchers to develop
standard operating procedures for clinical trial units that
intend to use qualitative methods within traditional RCT
designs [16]. Previous studies have successfully used quali-
tative research methods to improve recruitment to RCTs
(for example The ProtecT [Prostate testing for cancer and
Treatment], [17]). The Medical Research Council (MRC)
has also identified the value of incorporating qualitative
studies to RCTs (in mixed methods paradigms) [18].
Methods
A focus group design was used for this study. Focus groups,
rather than individual interviews, were considered because
it allowed us to collect a large corpus of data within a short
period of time from a large number of people. Furthermore,
as Gibbs [19] suggests, the attitudes, feelings, and beliefs of
participants that may be partially independent of a group
(or its social setting) are more likely to be revealed through
interaction between group members. Participants were
recruited who met the inclusion criteria for the ECLS
trial: age 50 to 75 years; current or former cigarette smokers
with at least 20 pack-years, or a history of cigarette
smoking plus family history of lung cancer; and living
in the four catchment areas the main trial intends to
recruit from, covering some of the most disadvantaged
areas in Glasgow (Castlemilk and Darnley) and Dundee
(Charleston and Douglas). We considered the focus
groups provided patient and public involvement and
did not seek other contributions from patients or the
public to this stage of the pretrial work.
Recruitment took place in shopping centers and on
streets close to other facilities such as community centers.
Recruiters worked to broad quotas per group for age
(50 to 59, 60 to 69, 70 to 75; quota minimum 3 per group),
gender (quota: 5 male, 5 female), catchment area (10
per area), and working status (a diverse range fulfillingthe following categories: full time (30 hours plus), part-time
(8 to 29 hours), retired, house person, unemployed, student,
long term sick, disability allowance), aiming to recruit
10 participants to each focus group. The focus groups
were held during two afternoon and two evening ses-
sions to allow people of different working status to at-
tend (full time workers were more likely to be available
to attend evening meetings). To maximize accessibility
and familiarity of venues among participants, all groups
were held in local community centers. We believed that
this would enable us to get a diverse range of views from
people who would potentially be eligible to take part in
the trial. Groups were facilitated by one of the authors
(KSO) and lasted approximately two hours. All participants
received a £30 cash incentive for taking part, given at the
end of the sessions.
A topic guide, based on previous literature and discus-
sions with the researchers of the main trial, was devel-
oped for the focus group sessions (see Appendix). This
covered a range of topics, including: likely willingness to
take part in such a trial, barriers and facilitators to par-
ticipation, understanding aspects of the trial (such as
the concept of randomization, need for a control group,
and so on), and views on various draft materials that
had been developed for the main trial. Draft material
given to the participants to comment on included: GP
letter, PIL, and a summary sheet explaining the study in
brief. We also displayed show cards with different re-
cruitment options, a flowchart explaining the trial, and
examples of leaflets used in other trials (to demonstrate
different formats of conveying study information).
Written consent to participate was obtained from all
participants. All sessions were digitally recorded and ver-
batim transcripts were produced to facilitate analysis. A
combined inductive and deductive approach to thematic
analysis was conducted [20]. All transcripts were read
by two of the authors (RdN and KSO), and the core
messages highlighted and extrapolated. These underwent
an assimilation process so that similar responses were
clustered together, which were then used to structure
presentation of findings. Through discussion, we came
to an agreement of the clustering of the data. We did
not aim to achieve data saturation. This is a contested
term in qualitative research and there are strong arguments
against the use of data saturation as a quality indicator
[21,22]. Transparency is considered more important
than concepts such as saturation [21]. Therefore, we opted
to follow Spencer et al. [23] to demonstrate transparency
by ensuring sampling adequacy (in using a form of quota
sampling) provided both depth and opportunities for trans-
ferability of findings (as reported in [21]). Furthermore, we
explicitly provide excerpts from the data as participant
quotes that exemplify the theme, so readers can see how
the participant data maps onto our themes. For this study
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to build and work on constructs that emerged from the
data. There was no member checking done. While member
checking (or respondent validation) has been conducted
in some studies, we followed the cautions of member
checking raised by qualitative researchers such as Morse
[25], Angen [26] and Sandelowski [27], who offer a com-
prehensive critical review of the use of member checks
for establishing the validity of qualitative research.
The study was granted ethical approval from the Institute
of Work, Health & Organisations at the University of
Nottingham, UK.
Results
The sample
A total of 116 people were approached to take part. Of
these, 40 (34%) agreed to participate, 15 were ineligible,
and 61 declined. Of the 15 people who were ineligible,
11 did not meet the relevant smoking status criteria and
four were under 50. Of the 61 people who declined to
participate, 24 were not interested in taking part or gave
no reason for refusal, 14 did not have the time, 8 were
working at the time of the focus group, 7 had other
responsibilities, 4 did not feel well enough to attend, 2
were not interested in stopping smoking and did not
want to be advised about smoking, and 2 did not want
to go out in the local area at night. Overall, there was
little difference in nonparticipation by gender, with 37
women and 39 men declining, or ineligible to take part,
with the exception of one site where it proved more
difficult to recruit men than women. The average age of
participants who agreed and declined to participate was
63 and 64 respectively. The groups did, however, differ
somewhat in terms of working status, with the majority of
those who agreed to participate being retired (47%), and
the majority who declined being unemployed (49%).
Of the 40 people who agreed to participate, 32 (18
female, 14 male) attended one of the four focus groups. The
mean age of participants was 63 years (range 50 to 75). The
working status of the participants is described in Table 1.Table 1 The working status of participants, by gender
Working Status Male Female All
Full Time 2 (6%) - 2 (6%)
Part Time - 4 (13%) 4 (13%)
Retired 7 (22%) 8 (25%) 15 (47%)
House person - 2 (6%) 2 (6%)
Unemployed 1 (3%) 4 (13%) 5 (16%)
Long Term Sick 2 (6%) - 2 (6%)
Disability Allowance 2 (6%) - 2 (6%)
All 14 (44%) 18 (56%) 32 (100%)Of the 32 people who participated, almost all were
current smokers (n = 31; 97%), with only one person
stating that they had stopped smoking. The majority
of participants reported smoking for 40 years or more
(n = 28; 88%). Only four participants (12%) reported
smoking for more than 20 years, but for less than 40 years.
Almost all participants reported smoking one pack or
more per day (n = 26; 81%), with only six (19%) reporting
smoking less than one pack per day.
This paper presents our findings in relation to participant
views regarding recruitment strategies only. Three
themes were developed under the superordinate theme
of recruitment strategies: recruitment options, understand-
ing randomization and issues related to the control group,
and perceived barriers and facilitators to participation. Each
of these is considered below. To protect the anonymity of
participants we present only their gender, age, and location.
Recruitment options
A dedicated section of the focus group sessions explored
the various recruitment options that could potentially be
used for the main trial. Participants were asked to con-
sider the following options: (A) sending a letter from
GPs, with a free post envelope, asking patients to send
back a reply slip to show if they are interested and pro-
viding contact details; (B) phoning patients who do not
send back the reply slip to see whether they are inter-
ested (the letter from the GP would make it clear to
people that they should contact the trial team if they do
not want the trial team to contact them); (C) researchers
handing out leaflets about the study to patients when
they go to the GP surgery; (D) GP practice receptionists
handing out leaflets to patients when they book in to
see the GP or nurse, or when they collect a repeat pre-
scription; or (E) GPs and nurses asking patients when
they see them in consultations if they have not responded
to study invite letters.
The invitation to participate
The groups expressed quite different views with regards
to the use of a GP letter as a means of recruiting into
the study (option A). In Castlemilk (Glasgow, UK), there
were no objections to this although some participants
questioned whether GPs would really be on board for a
study of this kind, and participants suggested that GPs
were too remote and difficult to engage with:
‘Not through the GP. I wouldn’t bother contacting
them and asking them to do it, ‘cause they’re
hopeless.’ (Male 57, Castlemilk)
‘Cause sometimes, they [GPs] don’t even know what
they’re doing. I don’t think that [health] center is up
to date, and it takes you a week [to get an
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better.’ (Female 57, Castlemilk)
A further concern raised was as to whether the prepar-
ation and postage of letters would distract GPs from their
routine activities. Despite this, the majority of participants
in Glasgow seemed satisfied that the GP letter approach
would work well, and most indicated that they would re-
spond to such an invitation. In Charleston (Dundee, UK),
however, some respondents expressed stronger reserva-
tions about whether the GP letter approach would work.
People talked about letters being set aside, binned and es-
sentially treated as junk mail:
‘Well, the first thing you would do with that [GP
letter and reply slip] is bin it.’ (Male 64, Charleston)
Although there was some skepticism about the effect-
iveness of a letter from the GP in securing the desired
response rates, participants appreciated the fact that a
choice was given to reply and to express whether they
would or would not be interested. They also appreciated
that the letter encouraged people to think about the
study after reading the leaflet, before making a decision:
‘I think [option] A is the best one out them all…. You
know, send the slip back to say “Yes, you want to take
part”, or if they’re not interested, don’t send it back,
you know…’ (Male 64, Darnley)
‘It’s asking you to think about it as well, not just if you
want to, it’s saying take your time and think. That’s
nice.’ (Female 65, Castlemilk).
Nobody supported the idea of leaflets being handed
out at the GP surgery (options C and D), either because
they felt they were unlikely to visit the GP surgery (in order
to be given a leaflet there) or that people would simply pay
no attention to leaflets:
‘I don’t think they should give out leaflets, ‘cause so
many people just put them in their pockets and
that’s it… It’s a complete waste of time.’
(Female 54, Douglas)
Similarly, in both Glasgow and Dundee, respondents
mentioned that they did not regularly visit their GP and
so the consultation approach (option E) would not work:
‘It depends how often you see your GP. For example,
the last time I saw my GP was when I got my hip
replacement four years ago. Now, possibly, I’m lucky.
But if I’m never near my GP, then that option isn’t
gonna work for me, you know.’ (Male 66, Charleston)‘Me either. I mean, it’s two years, or three years, and it
was fourteen years before that before I was at my
doctor.’ (Female 62, Charleston)
Only a minority of participants felt that a face-to-face
invitation from the GP would be the best approach to
take, because it was more direct and personal.
A small number of participants suggested that leaflets
handed out whilst collecting repeat prescriptions may work:
‘I think the leaflet when you’re getting your repeat
prescription. ‘Cause let’s face it, everybody goes for
their repeat prescription.’ (Female 57, Castlemilk)
Focus group participants made an alternative sugges-
tion to the GP invitation, which was word of mouth.
Whilst the trial catchment areas were large, disadvan-
taged areas cluster in well-defined locations, and so
word of the study was likely to spread amongst people
in these areas. Different forms of media, especially
local papers and the radio, were also seen as potentially
useful for raising awareness about the study, which
may make people more comfortable about taking part
(giving the study a local public profile). However, the idea
of study posters received mixed views. Some suggested
they may be useful if they were posted in GP surgeries,
hospitals or local community centers, but others ques-
tioned the impact they would have.
Following up the study invitation
Views regarding the follow-up of non-responders were
mixed. Although people generally acknowledged that
the principle of follow-up was a good idea, especially
to capture people who genuinely wanted to take part
but who had forgotten to respond, people in all groups
almost unanimously did not like the idea of follow-up
telephone calls for non-responders (option B). The general
perception was that follow-up calls from a researcher
or receptionist would be viewed as akin to a sales and
marketing call:
‘The phone…it’s always somebody trying to sell you
something. You know, how many times in the day do
you get that?’ (Male 75, Darnley)
The idea of follow-up reminders by text messaging
was also dismissed. The most popular option to follow-
up non-responders was being asked directly by GPs
(or receptionists) during routine appointments:
‘Well, see when you go to your Doctor normally
anyway. Well, how can he not be able to ask you if
you want to participate?… ‘Cause you’re there
anyway.’ (Male 55, Douglas)
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to the control group
Understanding randomization
Some participants struggled to understand the concept
or need for randomization:
‘How do they choose? Say, likes of five will go for the
test and five will’nae, how do they actually choose?’
(Male 64, Darnley)
‘Is it an even, uneven numbers?’ (Female 65, Darnley)
‘Likes of, you know, if you’ve got somebody talking
about their health problems, is that how it’s
determined?’ (Male 64, Darnley)
However, these concerns were allayed by the facilitator
who was able to explain the scientific rationale for, and
process of random allocation. Participants reported feel-
ing more inclined to take part once this was explained
further, indicating the importance of explaining the need
for randomization in an understandable way. Participants
suggested ways of explaining randomization to their peers,
using terms such as half and half, picking names out of a
hat or like the lottery to reassure people that decisions
about groups were not based on personal characteristics:
‘I mean, the term “randomization” is clear, but how is
it done, is it through a computer or…I think I’d like
to see, maybe if they’re gonna do it like that it says
that they’re gonna pick it from the computer, names,
you know, so people know that the reason why they’re
not chosen is because of the computer. It’s like what
Radio Clyde do, the computer picks the winner!’
(Male 64, Darnley)
‘Like the lottery. That’s something that everybody
understands.’ (Female 71, Darnley)
Despite explaining random allocation, some participants
were still uncertain whether they would be selected on the
basis of some personal or illness characteristics:
‘I might be more worried if I was put in the test group,
that they maybe thought there was something there…
You’d think, “Oh my God, have they seen something?”
I think you would.’ (Female 57, Castlemilk)
‘Well, if someone is in poor health, maybe they should
have a better chance of being in the test group.’
(Female 65, Castlemilk)
This suggests that, for some, the randomness of the
allocation to study groups might still be questioned.
Furthermore, although participants perceived the randomapproach to be fair, most people expressed that they would
clearly prefer to be in the test (experimental) group:
‘I think most people would want to be in the ‘top
group’ (test group), but I think everybody is
prepared to know that they are going to be half and
half.’ (Female 54, Douglas)
Issues related to the control group
Some participants struggled with understanding the ra-
tionale for having a control group, and said that alloca-
tion to the control arm of the study would put them
off from participating:
‘Moderator: So, the fact that there’s a 50% chance that
you wouldn’t get tested means that you wouldn’t want
to take part?
Aye. If I was one of the 50% when they said, “Right,
we’re gonna take a sample from you and test it”, then
yeh, but if I was one of the 50% that didn’t get picked
(the control group), then no. I would rather not know,
actually. No.’ (Female 63, Charleston)
Some participants, however, understood this need and
attempted to convey this to others in the group, as evi-
denced in the following exchange:
‘I think if they’re gonna do the study, they should do
it to everybody (the test). The whole lot should have a
chance to.’ (Female 57, Castlemilk)
‘But that’s, they’ve got to be able to compare it with
people who have not been tested with it to see how
effective it is.’ (Male 56, Castlemilk)
‘But say like, they take 50 people, well, can they not
ask certain doctors to take part in and let the doctors
do the other 50 who are not taking part in it?’
(Female 57, Castlemilk)
‘They’ve got to have something they can measure it
against, it’s like a placebo. They’ve got to have
something to check against it.’ (Male 56, Castlemilk)
However, even for some people who understood the
need for a control group, they found it hard to appreciate
the need for this in a screening trial:
‘You can understand if it was a medication that was
coming out and it was a blind trial, they need people
to take the placebo and other people not, but you
would think it’s different with this kind of thing.’
(Male 64, Charleston)
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to describe the control group. Some felt that the label was
not clear:
‘I wasn’t very sure of it when I read it at first. I had to
think about it, “What’s the usual care group?” You
have to read through it before you realize what it is.’
(Female 69, Douglas)
‘It’s not really anything is it?’ (Female 69, Douglas)
‘I was gonna ask, “What is that?” but I thought,
“No, I’ll read on a bit”.’(Female 69, Douglas)
Others thought the term was misleading:
‘It makes it sound like you’re gonna get some kind of
care, but you’re not getting any kind of care.’ (Female
54, Douglas)
‘I don’t think that’s the right title for it.’ (Male 55,
Douglas)
Suggestions for alternative names for the usual care
group included: research care group, research group,
untested group, placebo, and non-test group.
Although the idea that people would be allocated at ran-
dom to one of the two groups did not appear to attract
any confusion among participants, this was the one area
of the study that did cause some to question whether or
not they would consider taking part in the main trial:
‘So, if I was told that I wasn’t going to be in the test
group, I would say, “Well, what’s the point in doing it
then?”’ (Female 71, Darnley)
‘It wouldn’t bother me, but it might bother a lot of
people – “Well, you’re not getting my blood then. If
I’m not gonna be in the test group, you’re not taking
my blood”.’ (Female 54, Douglas)
A view that was asserted in all groups was that the
blood test should be offered to all participants, and not
just half of them. Comments from some participants
demonstrated a lack of understanding of the scientific
nature of the study and the need for a control or com-
parison group:
‘Would they not be better, instead of having half of
the people not going through the full trial, could they
not put everyone in the full trial?… Surely, it must be
more beneficial to test 10,000 people to see if they’ve
got lung cancer than just 5,000 people in the trial?’
(Male 64, Charleston)
‘But, how are they only doing 50%? Why do they not
just test them all?’ (Male 63, Castlemilk)Clearer explanations of the rationale for randomization,
and how and when people would be informed of their
group allocation were therefore needed.
Perceived barriers and facilitators to participation
We class the perceived barriers as practical barriers and
psychosocial barriers. Of the former, the main obstacle
to participation appeared to be the need for flexible ap-
pointments that were local to participants. Reimburse-
ment of travel expenses was not considered important
to most as they had free bus passes. Among those who did
not qualify for bus passes because of their age, one said
that they would welcome the reimbursement and one did
not. Reimbursement of travel expenses was only seen as
necessary if appointments were further than the local GP
surgeries (at a hospital or elsewhere further from home).
While most of the respondents were retired, work com-
mitments among some of the younger participants were
seen as a potential barrier and so the need for flexible
appointments was perceived to be greatest for this
demographic (under 60s):
‘Well, your appointments would have to be flexible,
because people are still working. Not myself, I’m
retired, but there are always people working who
might not be able to get time off work.’ (Male 64,
Charleston)
With regard to perceived psychosocial barriers, partici-
pants felt stigmatized (because of their smoking status)
by some of the language used in the PILs (such as tar-
geting smokers, because of their higher risk of develop-
ing lung cancer). Some strong views were expressed that
cancer could affect anyone and smokers should not be
made to feel singled out or challenged:
‘You’re saying smokers, but there are people that have
got cancer that have never smoked in their life…’
(Female 63, Charleston)
‘There’s folk that haven’t smoked in their life. Folk
sitting in a pub, or sitting in a hall and catch it
[cancer].’ (Male 75, Douglas)
One possible barrier to recruitment was the perception
held by some participants that the trial is designed to
encourage people to stop smoking. The following ex-
change between the moderator and one participant
highlights this view:
‘Moderator: It’s [the PIL] preaching a wee bit?
Participant: Aye, “You smoke. Please stop ‘cause it’s
gonna give you lung cancer.”
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saying that you should stop (smoking)?
Participant: Yeah.
Moderator: ‘Cause, um, I should have said, if you took
part in the study no one would ask you to stop
smoking.
Participant: It was the same as when I was stopped in
the street (for recruitment), they were asking me if I
smoke, and how many I smoke, and you go, what do
you say? “Are you trying to get me to stop smoking?”
eh?’ (Female 63, Charleston)
This was evident in another exchange between the
moderator and a participant:
‘Participant: Would you want the person to stop
smoking if they took part in that?
Moderator: No.
Participant: It’s just that there’s lots of questions about
your smoking.’ (Female 57, Castlemilk)
Indeed, some participants believed that by taking part
in the trial and finding out that they had lung cancer
may force people to stop smoking, even though they did
not want to:
‘Giving up smoking… I’m just saying that if you’re
told you’ve got lung cancer, you’d stop smoking today,
you know what I mean? I think that would be hard
for a lot of people. Even if they said you’d got small
lung cancer…’ (Female 54, Douglas)
Such views were, however, contrasted with equal num-
bers of participants who said that they would continue
to smoke, regardless of what the test found:
‘I don’t agree with that. If I find out I’ve got cancer,
there’s no way I’m gonna stop smoking.’ (Female 57,
Castlemilk)
‘“Are you gonna give up smoking?” ’ Not a chance!
(Female 60, Darnley)
In general, participants felt that those who were
willing to participate would be committed to the trial
for its duration unless appointment times were too
rigid, there were too many appointments or appoint-
ments were too far away, or if they became unwell
during the study:
‘You’re either gonna take part or you’re not, once
you’ve got all the information, and once you’ve made
your choice, that’s it.’ (Male 56, Castlemilk)Altruism was perceived to be a motivator for partici-
pants, particularly for those in the control group who
saw their role in participating in the research, even to
the extent that they viewed the blood they were giving
(which was not going to be tested for the lung cancer)
as helping others:
‘The way I look at it is that I can’t do much for
‘mankind’, but if giving a wee vial of blood helps…. I
think that should be explained then when they go to
the nurse at the beginning when you’re told that not
in the test group, but you will be helping your fellow
man, or whatever you want to put it, you will be
helping. You will be contributing to the research.’
(Female 71, Darnley)
‘We’ve all got children, grandchildren, families, so if
it’s gonna help them eventually, then. ‘Cause it’s a
disease isn’t it? Lung cancer.’ (Female 60, Darnley)
‘Every little helps. Even if you’re helping somebody
else.’ (Male 56, Castlemilk)
‘But it is for medical research, it’s for the benefit of
others, so.’ (Female 54, Douglas)
Discussion
We conducted four focus groups to elicit views about
various aspects of the ECLS trial amongst members of
the public who matched the inclusion/exclusion criteria
for the trial. We felt this would enable us to refine our
trial procedures and participant facing documentation to
enhance recruitment in potentially hard to reach groups.
As Shaghaghi, Bhopal, and Sheikh [28] concluded in their
review of literature on recruiting hard to reach groups, re-
cruitment will depend on the characteristics of the group,
recruitment techniques used, and the subject of interest.
Our study enabled us to get a better understanding of the
characteristics of this group. We found that a combination
of approaches would be needed to meet the recruitment
preferences of those who took part in the focus group
sessions. We also found wide differences between focus
group members in terms of the regularity with which
they saw their GP, their likelihood of collecting regular
repeat prescriptions, and responding to postal invitations.
That said, overall the invitation letter from the GP was the
most popular of all recruitment options presented, followed
up either by a reminder letter or a face-to-face reminder
when participants next visited their GP (see Table 2 for
a list of changes made to the final study design and PIL
based on the feedback from the focus groups). The ap-
parent contradiction between the perceived usefulness
of face-to-face invites and face-to-face reminders from GP
may reflect participants’ experience, where non-attenders
Table 2 Themes, issues raised and changes made
Theme Issues raised Changes made to the study design or Participant
Information Leaflet (PIL) to address the issues
Recruitment options: How to
approach potential participants
Support for study information to be sent by GPs
or to be given in consultations
Recruitment therefore comprised:
Support for having a summary of the main points
in the PIL
a. Postal invitation letter including the study PIL with
a summary of the main points at the front of the PIL;
Lack of support for receptionists or researchers
handing out study information leaflets at the practice
and, where necessary or appropriate:
Participant suggestions that attaching PIL to repeat
prescriptions may be helpful
b. Invitation letter including a summary of the study
PIL on collection of repeat prescription;
Concern that those who don’t regularly go to the GP
would not be reached and need for other approaches
c. Invitation during consultation with GP/Practice
Nurse/Health Care Assistant at the practice;
Importance of hearing about study through “word
of mouth” and using the media to publicize study
d. Invitation to those eligible on registered research
volunteer databases
e. Posters in GP waiting rooms;
f. Other recruitment strategies including; Media campaign
involving: local and national newspapers; BBC Scotland;
local radio, celebrity endorsement
g. Publicity campaign using posters/leaflets etc. at
venues such as:
Football/Bingo halls/Bowling clubs; Smoking Cessation
Clinics; Hospital main entrances/hospital clinics; Shopping
Centers/Supermarkets/Pubs, etc.; Benefits offices/Post
offices, etc.; Sheltered Housing /Housing Associations
h. Community and charitable outreach programs, mobile
screening clinic, pharmacist approach through practices.
Recruitment options: How to
follow up non-responders
Acceptance of need to follow up non responders
to give people who genuinely wanted to take part
but who had forgotten to respond the opportunity
to do so
Study invite reply slip gives patients the option to specify
they do not want to be contacted again by research
team. Non-responders are followed up by mail with
one reminder. Practices will be offered the option of
using the Trial Torrent software package to identify
potentially eligible patients who do not respond to
postal study invites so that they can be approached
during routine primary care consultations.
Dislike of telephoning or texting non-responders
Support for non-responders being asked by GP
or nurse during consultations
Practical barrier: Appointment times Participants felt work commitments could be a
barrier to participation and flexible appointment
times would be needed
Those expressing interest in the study are sent the full
PIL and at least 24 hours after anticipated receipt are
phoned to discuss the study, answer questions, undertake
a preliminary eligibility assessment and to arrange a
recruitment visit at a time suitable to the patient. Patients
are reminded of the appointment by phone, text
message or email 48 hours prior to the appointment
depending on their preferred method of contact.
Psychosocial barrier: Stigma Participants felt stigmatized about being targeted
because of where they lived.
‘These [geographical] areas have been chosen because we
know that lung cancer is more common in these areas.’*
Participants felt targeted for being smokers and
wanted the researchers to acknowledge that
lung cancer can also occur in non-smokers.
‘Lung cancer can happen to anyone, including the young
and old and people who do not smoke, but the risk is
higher in those over 50 and those who have smoked.’
Participants were concerned that by taking part
in the trial, researchers would encourage them
to stop smoking.
We removed all mention of providing smoking cessation
information and advice from the PIL.
Issues related to the control group Participants did not like the use of the term
usual care group to describe the control group
We changed this to non-test group, which is what
participants were most comfortable with.
Participants did not always understand why
a control group was needed in the trial.
‘Whenever a new test is developed we need to find out
if it works. We do this by having a group of people who
have the test and a group of people who do not. Both
groups need to be similar so that we can compare
what happens to the people in each group.’
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Table 2 Themes, issues raised and changes made (Continued)
Some participants said they would be put off
from participating if they were assigned to
the control group
‘If you are in the non-test group, the information you
give us will be really important in helping us find out
if the new lung cancer blood test works, by comparing
what happens to both groups. By taking part, you are
playing an essential role in the research and could be
helping future generations.’
‘People in the non-test group are still playing a very
valuable role in the research by allowing a comparison
with those whose blood is tested, and could also be
helping future generations – ECLS Team’
Not understanding randomization Participants feared that they would be chosen
for some specific personal characteristic identified
by someone in the trial or their doctors
‘To try and make sure both groups are the same, each
person is put into a group at random. This is done by a
computer putting people into one of the two groups by
chance. This is the fairest way of deciding who gets the
test and means everyone will have a 50/50 chance of
being put in either group. This means that you are not
chosen to be in a group for any particular reason.’
Understanding the nature and
purpose of the test
Some participants thought the test would pick
up other health problems.
‘The test is only looking for lung cancer, so will not
pick up other types of cancer or other diseases.’
* Statements in quotes reflect the final wording used in PIL.
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their GP, as recommended in guides to maximize screening
attendance [29].
The themes, based on the focus group data, highlighted
mixed understanding and mixed feelings about various
concepts associated with RCTs. Based on these (mis)
understandings, potential participants may not have
taken part in the main trial. Participants grappled with
the concept of randomization and the need for a control
group, even with a facilitator being present to explain these
concepts. Not understanding the need for a control group
may deter participation and increase control arm dropout
rates. This highlights difficulties likely to be faced by trials
that first approach potential participants with a postal invi-
tation letter and/or PIL. Our participants did suggest alter-
native explanations, wordings and labels for randomization
and the control group, which they thought would make the
study clearer for potential participants.
When participants understood these concepts, the most
common reason for agreeing to participate, in the absence
of any personal gain, appeared to be altruism. Within rea-
son, most participants felt that even if they were allocated
to the control arm they would be happy for their blood to
be collected and to be used for other medical research. The
importance of altruism as a motivator for trial participation
is consistent with the findings of the systematic review by
Ross et al. [5].
Participants articulated some barriers that would pre-
vent them from participating in the main trial, especially
practical ones such as too few and lack of flexible ap-
pointment options, and attendance to research sites that
were not local to them. Some participants, however, felt
singled out or stigmatized because of their smoking
behavior, and wanted the PIL to be clear that it was not
only smokers who developed lung cancer. There was alsosome concern that the trial, if seen to be promoting smok-
ing cessation, would deter people from participating. These
perceived psychosocial barriers prompted us to carefully re-
consider, and make changes to all of our participant facing
material. It is important to note that, while the recruitment
sought to achieve a broad mix of demographics across a
range of geographical areas, the findings presented here
cannot be considered as representative of the communities
from which the participants were drawn, and instead only
provide indicative insight into the target population’s views.
We acknowledge that participant factors are only one as-
pect of recruitment, and that even with interest from po-
tential participants, removal of other institutional barriers
(such as those identified by Patterson et al. [30]) is essential
for adequate recruitment.
Conclusions
Focus groups provided us with useful information which
resulted in numerous changes to proposed trial docu-
mentation and processes in order to better address
participant’s information needs. Based on our findings,
we altered the language to reduce misunderstanding
regarding randomization and the control group, and to
ensure that smokers did not feel singled out for develop-
ing cancer. This was achieved in the following ways: we
removed mention of smoking cessation from our PIL;
we decided on the best ways to invite potential participants
to take part; and were reassured that our questionnaires
(particularly those related to smoking behavior) would not
alienate participants. The results from our focus groups
may be transferable to other community based screening
trials recruiting a similar participant pool. However, we
would recommend that trials, or feasibility studies for trials
budget for and conduct their own pretrial focus groups to
better recognize the issues that may influence participants’
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may be cost effective for the trial.
While some interventions to improve recruitment in
primary care trials have been assessed [31], and the use
of user testing to improve readability and understanding of
trial information for participants has been evaluated [10],
the effectiveness of pretrial engagement with a subgroup of
potential participants in improving participant facing mater-
ial to improve recruitment has not yet been systematically
evaluated. Further research is required in this area.
Appendix
Focus group topic guide
1. Brief introduction (2 minutes)
2. Aims of the FG: Explain the reason why they have
been invited to take part and the aims of this session
(3 minutes)
3. Summary Section from the Participant Information
Sheet: Go through the Summary section and see whether
this is clear (5 minutes)
– Having read this summary sheet, how well do you
think it explains what the study is about?
– Does the summary sheet raise any questions or
concerns for you?
what are they?
would they affect your willingness to take part?
would they affect your willingness to read on and
find out more about the study?Do you think this summary sheet is needed?
4. General questions about the study (5 minutes)
– Would the blood test be something you would
think about having?
– What kind of issues/concerns/worries would you
have about having such a blood test?
– Do you think there might be benefits of having
such a test? What might these be?
– Do you think there might be disadvantages to
having such a test? What might these be?
– With the information you have received so far, how
likely is it that you would take part in the study if you
were invited to? (ask all for a separate response)
5. Recruitment: Explain who we would like to recruit
(inclusion criteria) (15 minutes)
– We are thinking about several different ways to tell
people about the study and ask them if they might be
interested in taking part. At the moment we are
thinking about the following: [Use SHOW CARD 1]
Stress that 90% of GPs in the area have already
agreed to take part.– What do you think about these ways of getting
people involved in the study?
– Specifically, how would you feel about the letter
being followed-up with a phone call if you didn’t
respond? Would this bother you?
– What do you think of:
Radio? (which channels?)
Newspapers? (which ones?)
Word of mouth? (how would this work?)
Posters? (where?)
– Are there any other ways of asking people if they
want to take part that you think might work?
– What do you think of this letter? (Show example
GP letter)
– If it was you, how would you like to be invited to
take part in a study of this kind? (either choose
from the options listed or ‘other’) Take count.
6. GP Letter and Participant Information Leaflet:
(20 minutes)
– What do you think of this information leaflet?
– Is the language clear?
– Are there any words that are difficult to understand?
– Does it give you enough information to help you
decide whether you want to take part in the study?
– Is there anything missing that you would have liked
to have seen in the letter and leaflet?
– Is there too much information in the letter and
information leaflet?
– Is there anything that could be left out? If so, what?
– How clear is it about the advantages and
disadvantages (including the risks) of taking part in
the study? Please explain this in your own words, as
if explaining it to someone else.
– Do you understand what it would mean if the test
was positive? What would it mean if the test was
negative? Please explain this in your own words, as
if explaining it to someone else.
– Do you understand what a false positive test is? Do
you understand what a false negative test is? Please
explain this in your own words, as if explaining it
to someone else.
– Would you be happy to receive this information
through the post; or would it be better to receive
the summary and be able to go through the rest of
the information with a nurse?
– What do you think of this kind of leaflet?
(use Tascforce leaflet as example)
– What do you think of this kind of diagram, as a
way of explaining the study? (Use Flowchart)
– If you were trying to show someone what will
happen in the study, how would you do it?
(using images rather than words)
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7. Randomisation: Explain what this entails (including
clinical equipoise (i.e. we really do not know whether the
test will save lives or what the advantages and disadvan-
tages of having the test are for people) and terms such as
‘lung cancer test group’ and ‘usual care group’). Use SHOW
CARD 2 (20 minutes)
– How well does the information leaflet explain how
people will be chosen for the lung cancer test group
and the usual care group? (i.e. at random)
– How would you explain this to someone, in your
own words?
– Could we explain this any better? If so, how?
– What do you think about the way that people are
put into the two groups? (i.e. at random)
– How would you feel if you were told you had an
equal chance of being in the ‘lung cancer test group’
or the ‘usual care group’?
– If you were in the ‘lung cancer test group’, how
would that make you feel?
– If you were in the ‘usual care group’, how would
that make you feel? Would you still consider going
through to the end of the study?
– We have been talking about the control or usual care
group having their blood taken and it being used for
medical research. We would like to know how you
feel about having your blood taken if you are in the
control or usual care group? (Prompts- might this put
some people off taking part in the study? Would some
of you only think about taking part if the control or
usual care group didn’t have any blood taken at all?)
– Even if your blood was not going to be tested as
part of this study, would you still be happy for it to
be used by other researchers?
– What do you think of the label ‘usual care group’?
Does this sound negative? If so, why?
– It is important that people realise that, by being in
this group, they will still be making an important
contribution to the study. Is there another name
that you think would be better for this group?
8. Consent form: (5 minutes)
– What do you think about this consent form?
– Is it clear what you are agreeing/consenting to?
– Is the language clear? Are there any words which
are difficult to understand?
– Is there anything that needs adding or clarifying?
9. Questionnaires: (15 minutes)
– Are you happy with the number of questions you
have to answer?– Are there any of the questions about smoking that
you feel are inappropriate and/or you would not be
willing to answer and why?
– Do you have a preference (and if so why) on where
in the booklet these smoking questions are asked?
– [Re: the cancer worry scale] Are there any items
you do not like or do not understand? If so, why?
– [Re: the PANAS] Do you understand why we are
asking these questions? Please can you explain in
your own words?
– Questionnaires may take 10–15 minutes to
complete. How do you feel about that?
– Would you have a preference for when you would
receive this questionnaire? For example, before your
meeting with the nurse, or at the meeting?
– How would you like to respond to the questions?
 Answer them yourself?
 Have someone read out the questions and you
respond verbally, so that they can fill out the
questionnaires for you?
– Would you mind receiving the questionnaires in
the post, filling them out, and sending them back in
a pre-paid envelope?
– Would you mind completing the questionnaire over
the telephone?
– Are there any other ways you would prefer to
complete these questions (e.g., computer/web)?
– How would you feel about receiving £5 for every
questionnaire booklet you completed over
the study?
 Would it make you more or less likely to take part?
 Is £5 enough?
10. What will help people remain in the study and
prevent them from leaving prematurely? (15 minutes)
– If you thought that you might like to take part, is
there anything that might make it easier for
you to take part? (For example, reminders
about appointments, payment for childcare, travel
expenses, flexible appointment times, duration of
the study, the number of times you need to be
assessed, etc.)
– What could we do to make it easier for people to
take part in this study?
– If you joined the study, what might make it difficult
for you to stay in the study? (For example, summer
holidays, school breaks, travel to appointments, getting
time off work, too many questionnaires to fill in
(how many is too many?), etc.)
– What might make you want to stop taking part?
How likely are you to take part in the study?
(5 minutes)
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if you were invited to take part, how likely is it that
you would take part? (ask all for a separate response)
– If you have changed your mind from when we
asked you at the beginning of the group, what made
you change your mind?
Thank and close
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